2025-12-23 - Analysis Report
Okay, let's break down this analysis of Eli Lilly (LLY).

**0) Simple Numbers & Analysis**

**1) Return Rate Comparison**

*   **Ticker:** LLY (Eli Lilly and Co) - A pharmaceutical company.
*   **LLY Cumulative Return:** 305.60%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:**
    *   Max: 248.5
    *   Min: -33.6
    *   Current: 204.7
    *   Relative Divergence: 84.5

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) by a large margin. The current divergence of 204.7 shows the substantial difference in cumulative returns. A relative divergence of 84.5 indicates that the current outperformance is near the higher end of its historical range compared to the S&P 500. This suggests a strong recent period of outperformance relative to its past performance.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B)  |
|------------|---------|---------|---------|--------|---------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0%  | -0.0   | 76.1    |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%   | -0.0   | 104.2   |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%   | 0.4    | 118.4   |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%   | 0.4    | 152.1   |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%    | 0.5    | 248.8   |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%   | 0.4    | 329.5   |
| 2021-2023  | 125.0%  | 78.9%   | 124.0%  | 0.2    | 525.0   |
| 2022-2024  | 134.0%  | 81.2%   | 113.0%  | 0.2    | 695.3   |
| 2023-2025  | 197.0%  | 83.5%   | 132.0%  | 0.2    | 965.0   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR has seen explosive growth in recent periods, accelerating from 11% in 2015-2017 to an impressive 197% in 2023-2025.
*   **MDD (Maximum Drawdown):** MDD has fluctuated.
*   **Alpha:** Alpha is consistently positive, indicating LLY's ability to generate excess returns above its benchmark. The recent Alpha figures (113%-132%) are very high, reflecting significant outperformance.
*   **Beta:** Beta is low. A beta less than 1 implies the stock is theoretically less volatile than the S&P 500.
*   **Cap(B) (Capitalization in Billions):**  Market capitalization has grown substantially, reflecting the company's strong performance and investor confidence.

**2) Recent Stock Price Fluctuations**

*   **Close:** 1071.43994140625
*   **Last Market:** price: 1076.48, previousClose: 1071.44, change: 0.47
*   **5-day SMA:** 1057.318
*   **20-day SMA:** 1042.5557
*   **60-day SMA:** 931.1742

**Analysis:** The stock is trading above its 5-day, 20-day, and 60-day moving averages.  The short-term (5-day) SMA is above the medium-term (20-day) SMA, which is above the long-term (60-day) SMA. This indicates an upward trend in the stock price.  The small price change in the last market indicates a minor fluctuation.

**3) RSI, PPO Index & Other Indicators**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 55.59
*   **PPO (Percentage Price Oscillator):** -0.2291
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) Relative Divergence Change:** 5.8 (+)
*   **Expected Return (%):** 49.2%

**Analysis:**

*   **MRI:** Suggests a medium level of investment risk.
*   **RSI:** An RSI of 55.59 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** The PPO is slightly negative, which may indicate a slight downtrend in the momentum.
*   **Hybrid Signal:** This gives a "Buy" signal, suggesting strong confidence in the stock.
*   **Relative Divergence Change:** The recent increase in relative divergence indicates short-term upward momentum.
*   **Expected Return:** A very high expected return of 49.2% suggests significant potential for long-term gains, potentially driven by expectations of continued growth in the weight-loss and diabetes markets.

**4) Recent News & Significant Events**

*   **Weight-Loss Pill Focus:** Several headlines emphasize Eli Lilly's weight-loss drug, Zepbound, and its impact on the stock.  The price cut of Zepbound is mentioned.
*   **Analyst Optimism:**  Jim Cramer's comments suggest a positive catalyst for LLY.
*   **Institutional Investment:** Perpetual Ltd acquiring shares indicates institutional confidence.

**Analysis:** News sentiment is generally positive, revolving around the company's success in the weight-loss drug market, which likely fuels investor optimism. The price cut of Zepbound, while potentially impacting short-term revenue, could increase its market share.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (1.70)
*   **Target Price:** 1093.22 (avg) / 1500.00 (high) / 770.00 (low)

**Analysis:** Analyst consensus is strongly bullish with a "Buy" rating. The average target price suggests a slight upside from the current price, while the high target price indicates substantial potential growth according to some analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.3  | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2025-10-30 | 1.08 | 11.44 B$  |

**Analysis:** EPS and revenue are trending upwards. The most recent quarters show significant growth in both EPS and revenue. This positive trend supports the bullish sentiment.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $17.60B     | 82.91%        |
| 2025-06-30   | $15.56B     | 84.27%        |
| 2025-03-31   | $12.73B     | 82.53%        |
| 2024-12-31   | $13.53B     | 82.24%        |
| 2024-09-30   | $11.44B     | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-09-30   | $23.79B     | 23.46%    |
| 2025-06-30   | $18.27B     | 30.98%    |
| 2025-03-31   | $15.76B     | 17.50%    |
| 2024-12-31   | $14.19B     | 31.07%    |
| 2024-09-30   | $14.24B     | 6.81%     |

**Analysis:**

*   **Revenue:** Revenue has been increasing steadily, indicating strong sales growth.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability and efficient cost management.
*   **Equity:** Equity is increasing, reflecting the company's growing net worth.
*   **ROE (Return on Equity):** ROE is fluctuating but generally high, indicating that the company is effectively using shareholder investments to generate profits.

**7) Comprehensive Analysis**

Eli Lilly (LLY) presents a compelling picture of strong growth and outperformance.

*   **Exceptional Performance:** LLY has significantly outperformed the S&P 500, driven by its successful drug pipeline, particularly in the weight-loss and diabetes markets.
*   **Positive Momentum:** Recent stock price trends, coupled with a buy signal from the hybrid indicator and a positive change in relative divergence, indicate strong upward momentum.
*   **Strong Fundamentals:** Increasing revenue, high profit margins, and improving ROE support the company's growth story.
*   **Analyst Confidence:** The consensus "Buy" rating and optimistic target prices reflect analyst confidence in LLY's future prospects.
*   **Market Drivers:** News surrounding Zepbound and other developments in the weight-loss drug market are key catalysts.
*   **Risks:** High valuation should be considered. The high MDD in the past, indicates a history of price fluctuation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.